Registration is now closed.
World Congress on Thyroid Cancer 4.0
July 29 – August 1, 2021
Patients Thyroidectomized for Thyroid Cancer in Treatment with Oral Liquid L-Thyroxine (L-T4) Formulation
- Presentation Speakers / Moderators
Not many data are present in literature about the efficacy of levothyroxine (L-T4) liquid formulation in patients subjected to total thyroidectomy, hence our aim was to study the effectiveness of this treatment in comparison to L-T4 tablets in patients previously submitted to total thyroidectomy for thyroid cancer, with no malabsorption or drug interference issues.
One hundred and sixty patients were included in the study of whom eighty were treated with liquid L-T4 formulation, while eighty took L-T4 tablets; it was used the same dosage for both groups (1.5 mcg/kg/day). The treatments began the day after surgery and the drugs were administered 30 min before breakfast. Both groups were evaluated after 6 weeks (first control) and after 12 weeks (second controls) by measuring thyrotropic hormone (TSH), free thyroxine (FT4), and free triiodothyronine (FT3) serum levels.
Both in the first and in the second control, low TSH values [(P < 0.05) and (P < 0.01) respectively] were observed in the liquid L-T4 group with respect to the tablet L-T4 group; while no significative differences were observed for FT4 and FT3 levels. In the L-T4 tablet group, a significative high prevalence of patients in the hypothyroid range (TSH>3.6 mcU/ml) was found.
Discussion & Conclusion
To sum up, in patients subjected to total thyroidectomy for thyroid cancer, without issues of gastric disorders, malabsorption or drug interference, the control of TSH levels was obtained by L-T4 liquid with a better efficacy with respect to L-T4 tablets.
Two Approaches to Level 5 Neck Dissection
- Jeff Blumberg